Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
How do you approach HER2 directed therapy with discrepant results between FISH and Oncotype?
Especially if HER2 negative on pathological specimen
Answer from: Radiation Oncologist at Community Practice
At our institution, we don’t do Oncotype for HER2+ (by IHC or FISH) cases. See our published data showing the discrepancy.
Comments
Medical Oncologist at Stanford University, School of Medicine
Thank you so much for sharing this data!
Medical Oncologist at Joliet Oncology - Hematology Associates, Ltd.
What do you do if FISH is negative but oncotype is...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This is a very rare event and we have not changed ...
3153
3158
3159
Sign in or Register to read more
7878
Related Questions
Would you treat a patient with cT2 ER+/HER2+ breast cancer with neoadjuvant HER2 directed therapy if HER2 positivity is group 3?
What is your treatment approach in a patient with cT2 ER+HER2+ breast cancer who refuses neoadjuvant chemotherapy?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
Would you give adjuvant TDM-1 to a patient with HER2-positive breast cancer s/p NAC with TCHP found to have no residual disease in the breast, but presence of ITCs ypN0(i+) in one axillary lymph node?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
What are your top takeaways in Breast Cancer from ASTRO 2024?
Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you send Oncotype for pre-menopausal women with HR+, HER2(-) breast cancer with a small tumor (pT1b) and micrometastatic LN involvement or recommend adjuvant chemotherapy without sending Oncotype?
Thank you so much for sharing this data!
What do you do if FISH is negative but oncotype is...
This is a very rare event and we have not changed ...